Drug Trial Radar · NCT07744763
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
Mar 28, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is the first-in-human study of SYS6041, a multicenter, open-label, dose-escalation, dose-reassignment and cohort-expansion Phase I/IIa clinical study, which aims to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary antitumor efficacy of SYS6041 in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SYS6041Drug
Farletuzumab-exatecan antibody-drug conjugate targeting human FRα
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: 21 days
- ORRTime frame: Through study completion,up to 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiaohua
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.